Should sodium ‐glucose co‐transporter‐2 inhibitors be considered as first‐line oral therapy for people with type 2 diabetes?

Diabetes, Obesity and Metabolism, EarlyView.

Source: Diabetes, Obesity and Metabolism - October 4, 2018 Category: Endocrinology Authors: Kamlesh Khunti, Samuel Seidu, Melanie J. Davies Source Type: research